Peptidoglycan

Other Names

GlycopeptideMucopeptideMureinPGPGN

Synopsis

Peptidoglycan: A Comprehensive Reference

1. Identity, Nomenclature, and Natural Sources

Chemical Names and Synonyms

Peptidoglycan (abbreviated PGN or PG) is also known as murein, a term derived from the Latin murus (wall), reflecting its structural role. The compound is sometimes referred to as a glycopeptide polymer or mucopeptide in older literature. Its principal bioactive minimal fragment, muramyl dipeptide (MDP), carries the systematic chemical name N-acetylmuramyl-L-alanyl-D-isoglutamine. The structural monomer unit of the polymer is called a muropeptide.

Chemical Structure

Peptidoglycan is the major structural polymer in most bacterial cell walls and consists of glycan chains of repeating N-acetylglucosamine and N-acetylmuramic acid residues cross-linked via peptide side chains. More precisely, it is a critical component of bacterial cell walls that stabilizes the cell membrane while performing diverse physiological roles; it consists of a polysaccharide backbone cross-linked by peptide side chains forming a lattice-like sacculus that encases the entire cell. Tetrapeptide side chains, containing L-alanine, D-glutamic acid or D-glutamine, and either meso-diaminopimelic acid, L-lysine, L-hydroxylysine or ornithine, are attached to the carboxyl group of the N-acetylmuramic acid residues.

The fundamental structural component known as a muropeptide is well characterized, although modifications to this structure are common and often linked to specific physiological functions.

Natural Sources

Peptidoglycan is universally present in the cell walls of virtually all bacteria. It is estimated that in Gram-positive bacteria, peptidoglycans constitute about 70% of the whole cell wall, whereas the respective percentage in Gram-negative bacteria is about 25%. The cell walls of Gram-positive bacteria may contain up to 40 layers of peptidoglycan, conferring significant mechanical strength. Gram-negative bacteria have cell walls that contain mono or bilayered peptidoglycan and are more complex than the cell walls of Gram-positive bacteria.

From the perspective of dietary exposure and supplementation, humans are exposed to peptidoglycan through multiple routes:

The commensal gut microbiota, which continuously sheds PGN fragments into the intestinal lumen.
Fermented foods (yogurt, kefir, cheese, sauerkraut, and other traditionally fermented products), which harbor high densities of lactic acid bacteria whose cell walls are rich in peptidoglycan.
Experimental and pharmaceutical preparations derived from bacterial cell wall extracts, including muramyl dipeptide (MDP) and its synthetic derivatives used in research and clinical settings.
Inhalation of immunologically active airborne peptidoglycans represents an equally important and still underestimated route of exposure.

Common Forms and Preparations

Peptidoglycan is encountered in several distinct forms depending on context:

Polymeric PGN: The intact, high-molecular-weight sacculus isolated from bacterial cell walls, used in research and some pharmaceutical preparations.
Muropeptides: Fragments produced by enzymatic hydrolysis of the polymer (e.g., by lysozyme or other muramidases), the forms most often found circulating in blood and tissues during microbial exposure.
Muramyl dipeptide (MDP): A synthetic immunoreactive peptide consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln, first identified in bacterial cell wall peptidoglycan as an active component in Freund's complete adjuvant.
Lipophilic MDP derivatives: Compounds such as mifamurtide (MTP-PE) and romurtide, engineered for clinical use.
Probiotic-derived PGN: Material released from or associated with commercially available probiotic bacteria used in dietary supplements.

2. Traditional and Historical Use

Pre-Scientific Use Through Fermented Foods

Peptidoglycan itself was not recognized as a distinct chemical entity by traditional cultures; however, humans have been consuming PGN-rich materials for millennia through fermented foods. Fermented dairy products, fermented vegetables, and fermented grain preparations have been central to diets across nearly every human civilization — from Mesopotamian kefir traditions and Central Asian fermented milks to the sauerkraut traditions of Northern Europe and the kimchi traditions of East Asia. The bacterial cell walls in these foods, particularly those of lactic acid bacteria such as Lactobacillus and Bifidobacterium species, contain substantial quantities of peptidoglycan, and the immunostimulatory effects later attributed to PGN were thus experienced, if not understood, for generations.

Freund's Adjuvant and the Discovery of MDP

The modern scientific history of peptidoglycan as a bioactive entity begins with early 20th-century research into vaccine adjuvants. Complete Freund's adjuvant (CFA) — a mixture of killed mycobacteria in oil emulsion — was observed to dramatically boost immune responses to antigens. Research during the 1960s and 1970s sought to identify the active immunostimulatory component of CFA. Muramyl dipeptide (MDP) is a component of the peptidoglycan polymer and was shown to be an active but low-toxicity component of complete Freund's adjuvant, a powerful adjuvant composed of mycobacteria lysates in an oil emulsion.

Soon after the recognition of MDP as being the minimal subunit responsible for the activity of Freund's complete adjuvant, a great number of derivatives were synthesized. Because of their very low molecular weight it was hoped that they could retain selectively certain of the numerous effects produced by complex bacterial agents. Evidence was gathered showing MDP's direct effect on lymphocytes and on macrophages, and the ensuing studies revealed that MDP and several of its derivatives have marked immunopharmacological and neuropharmacological activities.

Structural modifications of MDP and its derivatives have been extensively studied in an attempt to increase adjuvant activity and boost the immune response effectively for clinical use in the treatment of cancer and other diseases.

Sleep Research and Endogenous PGN ("Factor S")

A parallel and remarkable thread of peptidoglycan's scientific history arose from 1970s sleep research. Researchers including Pappenheimer and colleagues identified a sleep-promoting substance isolated from the cerebrospinal fluid of sleep-deprived animals, termed "Factor S." Subsequent chemical analyses in the 1980s revealed Factor S to be a muramyl peptide — a fragment of bacterial peptidoglycan. Krueger and colleagues showed that slow-wave sleep (SWS) factor was a muramyl peptide of a molecular weight close to 1,000 daltons, and that MDP and several of its synthetic analogs had somnogenic activity. This line of research represented one of the first demonstrations that bacterial cell wall fragments could have direct neuropharmacological effects in mammals, suggesting an evolved interface between host sleep regulation and microbial sensing.

3. Key Constituents and Active Compounds

Structural Units

The peptidoglycan comprises alternating N-acetylglucosamine (NAG) and N-acetylmuramic disaccharide (NAM) saccharides, the latter of which has a peptide stem. Adjacent peptide stems are cross-linked by the transpeptidase enzymes of cell wall biosynthesis to provide the cell wall polymer with the structural integrity required by the bacterium.

Muramyl Dipeptide (MDP)

Muramyl dipeptide (MDP) is the minimal essential structural unit of PGN responsible for its immunological activity. MDP is the decomposition product of Gram-negative and Gram-positive bacterial peptidoglycan, which is released during the growth and division of bacteria. Muramyldipeptide (MDP; N-acetylmuramyl-l-alanyl-d-isoglutamine) is a common and key structure of PGNs and exhibits most of the bioactivities of PGNs.

Desmuramylpeptides (DMPs) and DAP-Containing Fragments

A second class of bioactive PGN fragments includes those containing meso-diaminopimelic acid (mesoDAP or DAP), which are found predominantly in Gram-negative bacteria. The minimal subfragments of peptidoglycan recognized by NOD1 and NOD2 are M-TriDAP (muramyl-N-acetyl-L-Ala-D-Glu-m-diaminopimelic acid) and MDP (muramyl dipeptide) respectively, which bind to the C-terminal LRR (leucine-rich repeat) domains of these proteins. Another bioactive moiety of PGNs, diaminopimelic acid (DAP)-containing desmuramylpeptides (DMPs), senses another intracellular receptor, NOD1.

4. Established Mechanisms of Action

Pattern Recognition: NOD1 and NOD2

NOD1 and NOD2 are pattern recognition receptors of the innate immune system with well-established roles in sensing fragments of bacterial peptidoglycan. NOD1 and NOD2 are intracellular pattern-recognition molecules of the NLR (Nod-like receptor) family; these proteins are implicated in the detection of bacterial peptidoglycan and regulate pro-inflammatory pathways in response to bacteria by inducing signalling pathways such as NF-κB and MAPKs.

NOD1 and NOD2 interact with a protein kinase called RIP2 (receptor-interacting protein 2), which is required for downstream signalling. NOD1 and NOD2 acting via RIP2, switch on the transcription factor NF-κB and the MAPKs — p38α MAPK, JNK, and ERK1 and ERK2 — which stimulate production of the pro-inflammatory cytokines that mount innate immune responses to combat invading bacteria.

The Nod proteins act independently of the TLR (Toll-like receptor) cascade, but potently synergize with the latter to trigger innate immune responses to microbes. The specificity of each receptor is distinct: Nod1 recognizes meso-diaminopimelic acid (mesoDAP)-containing peptidoglycan found predominantly in Gram-negative bacteria, while Nod2 detects peptidoglycan found in Gram-positive and Gram-negative bacteria.

TLR2 Signaling

In addition to NOD receptors, intact polymeric peptidoglycan also activates cell-surface pattern recognition. Staphylococcal PGN not only co-localizes with Nod2 but also with TLR2, and PGN is able to stimulate the immune system via both receptors. The immune responses induced by Nod2 and TLR2 are comparable and the two receptors act additively. Polymeric PGN interacts with both TLR2 and NOD2, while smaller MDP fragments primarily signal through the intracellular NOD2.

Synergy Between NOD and TLR Pathways

In human monocytic cells, both MDP and DMPs exhibited definite activities; marked synergistic interleukin (IL)-8 secretion was induced by DMPs and MDP in combination with synthetic TLR agonists, and suppression of the mRNA expressions of NOD1 and NOD2, respectively, by RNA interference specifically inhibited synergistic IL-8 secretion. In human dendritic cells (DCs), synergistic T helper type 1 responses are induced by combined stimulations of synthetic NOD and TLR agonists. In host-bacteria interactions, host cells recognize bacteria via both TLRs and NODs, which might induce synergistic innate and adaptive immune responses.

Polymeric vs. Monomeric PGN Internalization

Immune cells encounter both PGN polymers and hydrolyzed muropeptides during infections, and primary human innate immune cells respond better to polymeric PGN than the minimal bioactive subunit muramyl dipeptide (MDP). While MDP is internalized through macropinocytosis and/or clathrin-mediated endocytosis, the internalization of particulate polymeric PGN occurs via distinct mechanisms. Pharmacologic inhibition indicates that PGN primarily, but not exclusively, is internalized by actin-dependent endocytosis, while an alternate clathrin-independent but dynamin-dependent pathway supports 20–30% of PGN uptake.

Peptidoglycan Recognition Proteins (PGRPs/PGLYRPs)

Beyond the NOD/TLR axis, the host expresses dedicated peptidoglycan-binding proteins with their own distinct functions. Peptidoglycan recognition proteins (PGRPs or PGLYRPs) are innate immunity proteins that are conserved from insects to mammals, recognize bacterial peptidoglycan, and function in antibacterial immunity and inflammation. Mammals have four PGRPs — PGLYRP1, PGLYRP2, PGLYRP3, and PGLYRP4. They are secreted proteins expressed in polymorphonuclear leukocytes (PGLYRP1), liver (PGLYRP2), or on body surfaces, mucous membranes, and in secretions such as saliva and sweat (PGLYRP3 and PGLYRP4).

Three PGRPs — PGLYRP1, PGLYRP3, and PGLYRP4 — are directly bactericidal for both Gram-positive and Gram-negative bacteria and have no enzymatic activity, whereas PGLYRP2 is an N-acetylmuramoyl-L-alanine amidase that hydrolyzes bacterial cell wall peptidoglycan. In mammals, peptidoglycan is recognized by Nod-like receptors, PGRPs, CD14, Toll-like receptor-2, mannose binding lectin, RegIIIγ C-type lectin, and lysozyme.

Adaptive Immune Priming

Innate immune sensing of peptidoglycan by Nod1 is key for priming antigen-specific T cell immunity and subsequent antibody responses in vivo. Nod1 stimulation alone was sufficient to drive antigen-specific immunity with a predominant Th2 polarization profile. In conjunction with TLR stimulation, Nod1 triggering was required to instruct the onset of Th1, Th2, and Th17 immune pathways.

5. Scientific Evidence by Area of Use

5.1 Innate and Adaptive Immunity Modulation

The immunomodulatory activity of peptidoglycan and its fragments is among the best-characterized areas in microbiology and immunology. The evidence at the mechanistic (in vitro and animal model) level is very strong and reproducible across laboratories.

Probiotics are well recognized for their ability to modulate host immune responses; however, growing evidence indicates that many of their beneficial effects are mediated by structural components rather than by viable microorganisms. Among these components, probiotic-derived peptidoglycan has emerged as a key immunologically active molecule with a critical role in regulating both innate and adaptive immunity.

Evidence strength: Mechanistic understanding is robust in cell culture and animal models. Direct human clinical trials using purified peptidoglycan preparations as standalone immunomodulatory agents remain limited, and most human evidence comes from probiotic trials where PGN is one of many active components.

5.2 Gut Health and Intestinal Inflammation

Peptidoglycan plays a recognized role in gastrointestinal mucosal immunity. NOD2 recognizes conserved motifs of bacterial peptidoglycan and maintains mucus layer activity; thereby, NOD2 deficiency or mutation might lead to pathogen overgrowth, inflammation, and colon cancer.

In animal models, in a DSS-induced murine colitis model by Li et al. (2025), dietary supplementation with peptidoglycan alleviated key disease symptoms, including weight loss, colon shortening, and elevated disease activity index (DAI) scores. Additionally, by strongly triggering NOD2 signaling, probiotic-derived peptidoglycan fragments may inhibit inappropriate inflammation and improve epithelial barrier function and immune tolerance in the gut.

Evidence strength: Strong mechanistic and animal-model evidence; limited controlled human trials evaluating purified PGN specifically for intestinal inflammation exist as of 2026. The role of NOD2 in human gut disease is established at the genetic/epidemiological level (see Section 5.3 below).

5.3 Inflammatory Bowel Disease (Crohn's Disease) and NOD2 Genetics

The most clinically established connection between peptidoglycan biology and human disease is the relationship between NOD2 mutations (impaired PGN sensing) and Crohn's disease.

Crohn's disease is a chronic inflammatory bowel disease with a multifactorial pathogenesis involving environmental and genetic factors. Since the late 20th century, the discovery of the first susceptibility gene (NOD2, previously referred to as CARD15) for CD has paved the way for further investigations into the correlations between clinical features and genetics. NOD2 is the most relevant susceptibility gene for Crohn's disease.

The NOD2 gene encodes an intracellular receptor for bacterial peptidoglycan muramyl dipeptide, which, upon stimulation, forms an active oligomer capable of triggering a proinflammatory signaling cascade or stimulating autophagy through association with ATG16L1. The functional impact of NOD2 variations ensues in the loss of proinflammatory signaling, impaired autophagy, and reduced bacterial clearance, which lead to the upregulation of alternative inflammatory pathways, comprising interleukin IL-1β, IL-18, and the activation of the NLRP3 inflammasome.

Mutations in NOD2 have been shown to confer susceptibility to several chronic inflammatory disorders, including Crohn's disease, Blau syndrome, and early-onset sarcoidosis, underscoring the role of NOD2 in inflammatory homeostasis. Mutations in the NOD2 gene are found in approximately one third of Crohn's disease patients.

NOD2 is a putative receptor of bacterial peptidoglycan which is also expressed by Paneth cells and crypt epithelial cells. Mutations in the NOD2 gene are linked to reduced α-defensin expression in Crohn's disease.

Evidence strength: This is one of the best-replicated gene–disease associations in gastroenterology, supported by genome-wide association studies (GWAS), family studies, and functional experiments. It establishes impaired peptidoglycan sensing (via defective NOD2) as a significant contributor to disease susceptibility, though the mechanism is complex and NOD2 mutations are neither necessary nor sufficient alone to cause Crohn's disease.

5.4 Sleep Regulation

One of the more biologically surprising areas of PGN research concerns its somnogenic (sleep-inducing) properties. Several decades ago it was shown that some MDP-type PGNs induce prolonged (6–12 h) increases in slow-wave sleep (SWS) in rabbits, rats, and monkeys, and enhanced the amplitude of electroencephalogram (EEG) slow waves (0.5–4.0 Hz) during bouts of SWS.

The somnogenic properties of muramyl peptides are dependent upon their precise biochemical structure, and can be distinguished from other activities of muramyl peptides such as induction of fever and adjuvant activity. Moreover, PGN fragments were detected in the CSF and brain of sleep-deprived animals and human urine, implicating PGN in the pathophysiology of sleep disorders.

Amidation of the free gamma-carboxyl of MDP and several of its analogs resulted in the loss of somnogenic activity, demonstrating that sleep-promoting properties are dependent on specific structural features rather than being a general property of all muramyl peptides. Some analogs possess immunostimulatory and pyrogenic activity but not somnogenic activity, thus suggesting that these biological activities of muramyl peptides may, in part, be mediated by separate mechanisms.

Muramyl peptides (MPs) are bacterially derived sleep factors which stimulate slow wave sleep. In the neonate, MPs are capable of inducing quiet sleep and suppressing active sleep.

Evidence strength: The somnogenic activity of muramyl peptides is well-established in animal studies across multiple species. Human data remain largely inferential (urine detection of PGN fragments, correlation with microbiome status). No controlled human clinical trials have evaluated PGN or MDP preparations specifically for sleep outcomes.

5.5 Vaccine Adjuvant Activity and Cancer Immunotherapy (MDP Derivatives)

The most clinically advanced application of peptidoglycan-derived compounds is in the form of synthetic MDP derivatives used as pharmaceutical agents.

Mifamurtide (MTP-PE; liposomal muramyl tripeptide phosphatidylethanolamine): Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma approved in Europe in March 2009. It is indicated for the treatment of high-grade, nonmetastasizing, resectable osteosarcoma following complete surgical removal in children, adolescents, and young adults, aged two to 30 years.

The phase III clinical study of adjuvant liposomal muramyl tripeptide (MTP-PE) in resected high-grade osteosarcoma documented positive results that have been translated into regulatory approval, supporting initial promise for innate immune therapies in osteosarcoma.

In phase I and II clinical trials examining MTP-PE in patients with metastatic cancer, 28 patients with metastatic cancer received increasing doses (1-hour intravenous administration) of L-MTP-PE (0.05–12.0 mg/m²) twice a week. Peripheral blood monocytes were harvested and examined ex vivo for cytotoxic activity against human A375 melanoma cells. Activation of monocytes-mediated cytotoxic activity was seen in 24 (86%) of the 28 patients at some time points during the treatment period, and monocytes-mediated tumoricidal activity remained for up to 96 hours after initial mifamurtide infusion.

MDP activates cells primarily via the cytosolic NLR family member Nod2 and is therefore linked to the ability of adjuvants to enhance antibody production. Challenges posed by pyrogenicity, rapid elimination, and metabolic instability hinder the clinical utility of MDP.

Two lipophilic derivatives of MDP, romurtide and mifamurtide, are presently employed in treating leukopenia and osteosarcoma, respectively. The hydrophilic MDP derivatives murabutide and nor-MDP have undergone investigation in several clinical trials as potential vaccine adjuvants.

Evidence strength: The strongest clinical evidence exists for mifamurtide in osteosarcoma, which is a European Medicines Agency (EMA)-approved indication. Evidence for other MDP derivatives as vaccine adjuvants remains investigational.

5.6 Systemic Innate Immune Priming via the Gut Microbiome

Research has established that PGN fragments derived from the commensal microbiota circulate systemically and prime distant immune cells. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity, requiring signaling via Nod1, which recognizes mesoDAP-containing peptidoglycan found predominantly in Gram-negative bacteria.

Recent evidence indicates that NOD proteins can also recognize a broader array of danger signals. Indeed, recent work has expanded the roles of NOD1 and NOD2 to encompass not only sensing of infections with viruses and parasites but also perceiving perturbations of cellular processes such as regulation of the actin cytoskeleton and maintenance of endoplasmic reticulum homeostasis.

Evidence strength: Strong mechanistic and animal-model evidence demonstrating that microbiota-derived PGN fragments prime systemic neutrophil function and innate defenses. Human studies confirming this effect directly are emerging but not yet comprehensive.

5.7 Pyrexia (Fever) and Acute-Phase Response

Peptidoglycan has been shown to manifest itself clinically by reproducing most of the symptoms of bacterial infection, including fever, acute-phase response, inflammation, septic shock, leukocytosis, sleepiness, malaise, abscess formation, and arthritis. MDP and its derivatives are capable of producing hyperthermia by acting directly on thermoregulation centers or by inducing in vivo and in vitro endogenous pyrogens (EP).

Evidence strength: Well-established from human clinical observations during bacterial infections and from experimental studies. This is relevant primarily as a safety consideration (see Section 7).

6. Body Systems and Health Areas of Association

Immune System

The immune system is the primary biological system engaged by peptidoglycan. PGN and its fragments interact with innate immune cells (macrophages, monocytes, dendritic cells, neutrophils, natural killer cells) through NOD1, NOD2, TLR2, and PGRPs, activating cytokine cascades and inflammatory gene programs. They also participate in shaping adaptive immunity by priming antigen presentation and T cell differentiation.

Gastrointestinal System

The gut epithelium and associated immune tissue are continuously exposed to microbiota-derived peptidoglycan. NOD2 expression in Paneth cells of the small intestine is critical for antimicrobial peptide secretion and mucosal homeostasis. Dysregulation of PGN sensing in this system is associated with inflammatory bowel disease, particularly Crohn's disease.

Central Nervous System / Sleep Regulation

Muramyl peptides have documented effects on sleep physiology, with evidence for modulation of slow-wave sleep in multiple mammalian species, including the finding of PGN fragments in cerebrospinal fluid and urine. The mechanisms likely involve cytokine intermediaries (notably interleukin-1β) acting on sleep-regulatory circuits in the hypothalamus.

Cardiovascular and Sepsis Pathophysiology

Gram-positive bacteria, which lack LPS, are responsible for a substantial part of the incidents of sepsis with multiple organ dysfunction syndrome (MODS). The major wall components of Gram-positive bacteria, peptidoglycan and lipoteichoic acid, are thought to contribute to the development of sepsis and MODS.

Musculoskeletal System

MDP derivatives, specifically mifamurtide, have pharmacological activity relevant to osteosarcoma (a bone tumor). The broader musculoskeletal implications of peptidoglycan-induced joint inflammation have also been studied: certain analogs of muramyl dipeptide were shown to elicit activities including inducing acute joint inflammation.

Respiratory System

Airborne peptidoglycan from both indoor and outdoor environments (agricultural dust, livestock environments) represents a route of exposure associated with respiratory immune responses. While the relevant research literature is more closely linked to endotoxin (LPS), PGN from Gram-positive bacteria in organic dusts contributes to the overall inflammatory burden in occupational lung disease settings.

7. Dosage Forms and Reported Dosages

Because peptidoglycan is not marketed as a conventional dietary supplement with standardized dosing guidelines, dosage information is drawn from preclinical and clinical research literature for its pharmacologically studied derivatives.

Mifamurtide (MTP-PE) — Phase I cancer study: In the phase I study, 28 patients with metastatic cancer received increasing doses (1-hour intravenous administration) of L-MTP-PE ranging from 0.05 to 12.0 mg/m², administered twice a week.
Muramyl dipeptide — Sleep research (animal, rat): 250 μg/kg MDP was found to be immunosuppressive in sleeping rats but, paradoxically, the combination of such doses with sleep deprivation alleviated this effect.
Muramyl dipeptide — Sleep research (human study using intravenous MDP): The effect of intravenous administration of a non-pyrogenic (25 μg/kg) and a pyrogenic (2,000 μg/kg) dose of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) on sleep stages was tested.
Probiotic-derived PGN — colitis model (mouse): Dietary supplementation with peptidoglycan in a DSS-induced murine colitis model alleviated key disease symptoms including weight loss, colon shortening, and elevated disease activity index scores. No human-equivalent dosage was reported in this study.

There are no established dietary reference intakes, tolerable upper intake levels, or standardized clinical dosing recommendations for peptidoglycan or crude PGN as a dietary supplement from any major health authority (NIH, EFSA, WHO) as of 2026. Most exposure in dietary supplement contexts occurs indirectly through probiotic formulations, where the PGN content is not typically quantified or standardized by manufacturers.

8. Safety Considerations and Known Interactions

Pyrogenicity

MDP and several of its derivatives have marked immunological and pharmacological activities. Besides being adjuvants and capable of producing hyperthermia, they can also induce an increase of slow-wave sleep. The pyrogenic (fever-inducing) activity of MDP is a recognized safety concern for pharmaceutical development, which motivated the synthesis of modified derivatives with reduced pyrogenic profiles. Muramyl peptides possess immunostimulatory, pyrogenic, and somnogenic activities. The structural requirements for each of these activities are different, though muramyl dipeptide (NAM-L-ala-D-isogln) possesses all three activities. Some putative adjuvants have been developed specifically lacking somnogenic and pyrogenic activities.

Inflammatory and Septic Risk at High Concentrations

At pathologically relevant concentrations, as encountered during bacterial infections, peptidoglycan is a significant driver of systemic inflammation. Several studies have implicated a role of peptidoglycan (PepG) as a pathogenicity factor in sepsis and organ injury, in part by initiating the release of inflammatory mediators. Injection of native PepG into anesthetized rats caused moderate but significant increases in markers of hepatic injury and renal dysfunction in serum. In cultured macrophages, PGN synergized with lipoteichoic acid to augment inflammatory mediator production. These effects are relevant primarily in the context of systemic bacterial infection, not normal dietary exposure.

Proinflammatory Cytokine Release

Co-injection of MDP and LPS into mice enhances production of proinflammatory cytokines compared with mono-injection of LPS. Injection of MDP induces lethal shock in mice challenged with LPS. Furthermore, LPS and MDP synergistically induce proinflammatory cytokine expression in monocyte cell culture. This synergy between PGN fragments and bacterial endotoxin is biologically relevant in mixed infections.

Drug Interactions: Mifamurtide

Based on clinical experience with the approved MDP derivative mifamurtide, specific drug interactions have been identified. Theoretical considerations suggest calcineurin inhibitors like ciclosporin and tacrolimus might interact with mifamurtide because of their effect on macrophages. High-dose NSAIDs block the mechanism of mifamurtide in vitro. Consequently, the combination of mifamurtide with these types of drugs is contraindicated.

Side Effects of Mifamurtide in Clinical Trials

In a clinical study, mifamurtide was given to 332 subjects (half of whom were under age of 16) and most side effects were found to be mild to moderate in nature. Most patients experience fewer adverse events with subsequent administration. Common side effects include fever (about 90%), vomiting, fatigue and tachycardia (about 50%), infections, anaemia, anorexia, headache, diarrhoea, and constipation (over 10%).

Clinical Utility of PGN Analogs and Pharmacological Challenges

Challenges posed by pyrogenicity, rapid elimination, and metabolic instability hinder the clinical utility of MDP. These limitations have driven the development of modified structures (e.g., liposomal formulations, lipophilic conjugates) to improve pharmacokinetic properties and reduce adverse effects while retaining immunostimulatory activity.

NOD2 Mutations and Disease Risk

From a genetics perspective, it is notable that impaired rather than excessive PGN signaling through NOD2 is the major disease-associated direction in humans. MDP is detected in the cell by NOD2, a cytoplasmic receptor belonging to the human innate immune system. NOD2 mutations are frequently observed in patients with Crohn's disease, an autoimmune disorder, suggesting the significance of the MDP-NOD2 pathway in activating immunity. This implies that adequate physiological engagement of the PGN-sensing machinery may be important for normal immune homeostasis.

References

Health Conditions

Health conditions that Peptidoglycan may help support.

No conditions available.

Body Systems

Body systems that Peptidoglycan may help support.

No body systems available.